DeutschNewstral
Article
jdsupra.com on 2021-09-22 22:32
CHMP adopts positive opinion on Alvotech’s adalimumab biosimilar
Related news
- Amgen Receives Positive CHMP Opinion for its Biosimilar Adalimumabjdsupra.com
- Adalimumab Biosimilar Update: Shanghai Henlius Biotech’s Approval in China and Celltrion’s Positive Opinion in the EUjdsupra.com
- EMA Adopts Positive Opinion for Amgen’s Eculizumab Biosimilar Candidate BEKEMV®jdsupra.com
- EMA Adopts Positive Opinion for STADA and Xbrane’s Ranibuzumab Biosimilar Candidate XIMLUCI®jdsupra.com
- CHMP adopts positive opinions on two bevacizumab biosimilarsjdsupra.com
- CHMP Adopts Positive Opinion for Celltrion’s Herzumajdsupra.com
Novavax’s updated COVID-19 vaccine receives positive CHMP opinion in EU thedailyrecord.com- Sandoz’s High Concentration Adalimumab Biosimilar Application Accepted by EMAjdsupra.com
- Teva and Alvotech’s Adalimumab Biosimilar Receives Interchangeable Status at FDAjdsupra.com
- Centus Biotherapeutics Receives Positive Opinion for EQUIDACENT (Bevacizumab Biosimilar) in Europejdsupra.com
- EMA accepts adalimumab biosimilar applications from Fujifilm Kyowa Kirin and Sandoz, and an infliximab biosimilar application from Sandozjdsupra.com
- Recent Adalimumab Biosimilar Developmentsjdsupra.com
- Recent Adalimumab Biosimilar Updatesjdsupra.com
- EC Approves Amgen’s Biosimilar Adalimumabjdsupra.com
- China NMPA Approves Adalimumab Biosimilarjdsupra.com
- Biosimilar Updates: Epoetin, Rituximab, Adalimumabjdsupra.com
- Amgen Canada Launches Adalimumab Biosimilarjdsupra.com
- Boehringer Ingelheim Announces Positive Phase III Results for Its Adalimumab Biosimilarjdsupra.com
- FDA Approves Boehringer Ingelheim’s Adalimumab Biosimilarjdsupra.com
- Sandoz Obtains FDA Approval for Adalimumab Biosimilarjdsupra.com